Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.

The immunogenicity of recombinant modified vaccinia Ankara, a highly attenuated vaccinia virus, expressing influenza nucleoprotein (MVA-NP) and HIV-1 gag (MVA-gag) was investigated. Restimulation of peripheral blood lymphocytes of healthy subjects with MVA-NP led to expansion of CTL with specificity...

Full description

Bibliographic Details
Main Authors:	Dorrell, L, O'Callaghan, C, Britton, W, Hambleton, S, McMichael, A, Smith, G, Rowland-Jones, S, Blanchard, T
Format:	Journal article
Language:	English
Published:	2000

Similar Items

Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors.
by: Lalvani, A, et al.
Published: (1997)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
by: Ondondo, B, et al.
Published: (2006)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
by: Hanke, T, et al.
Published: (1999)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
by: Caroline Staib, et al.
Published: (2003-04-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.
by: Nixon, D, et al.
Published: (1988)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
by: Hanke, T, et al.
Published: (2007)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
by: Dorrell, L, et al.
Published: (2006)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Cytotoxic T lymphocytes in HIV infection
by: Rowland-Jones, S, et al.
Published: (1993)

Similar ligand densities required for restimulation and effector function of cytotoxic T cells.
by: Oxenius, A, et al.
Published: (1997)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
by: Mwau, M, et al.
Published: (2004)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
by: Sharpe, S, et al.
Published: (2003)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
by: Behboudi, S, et al.
Published: (2004)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Matthew G Cottingham, et al.
Published: (2008-02-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
by: Hanke, T, et al.
Published: (1998)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
by: Volker Sandig, et al.
Published: (2013-11-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Published: (2011-01-01)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
by: Slyker, J, et al.
Published: (2005)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
by: Schmidt, C, et al.
Published: (2008)

Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells.
by: Kündig, T, et al.
Published: (1993)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
by: Hanke, T, et al.
Published: (2008)

Recombinant Salmonella typhimurium strains that invade nonphagocytic cells are resistant to recognition by antigen-specific cytotoxic T lymphocytes.
by: Gao, X, et al.
Published: (1992)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, A, et al.
Published: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Pathan, A, et al.
Published: (2007)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
by: Rachael Chiam, et al.
Published: (2009-06-01)

Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus.
by: Feng, C, et al.
Published: (2001)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus.
by: Gotch, F, et al.
Published: (1991)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
by: C. Staib, et al.
Published: (2000-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
by: Mingwang Shen, et al.
Published: (2024-10-01)